top of page
About Us
Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. We are a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.
Leadership Team
Matthew A. Gonda, Ph.D.
President, CEO and Founder
Randall B. Riggs, MBA
Chief Business Officer
Shima Joshi, Ph.D.
VP, Regulatory Affairs
Vernon L. Alvarez, Ph.D.
SVP, Research & Development
Satish Joshi, Ph.D.
VP, Peptide Chemistry
Danny O. Helton, Ph.D.
VP, Chemistry & Manufacturing
Board of Directors
Matthew A. Gonda, Ph.D.
President, CEO and Founder
Lawrence W. Greer, DDS, MBA
Director
G. William Coble, II
Director
Daniel D. Canale, M.D.
Director
Thomas G. Andrews
Director and Founder
Dennis J. Carlo, Ph.D.
Director
Raymond Pirtle, Jr.
Director
bottom of page